Documents

Three differentiated oncology assets advance toward key clinical and commercial milestones in 2026.

Advancing clinical pipeline with major catalysts and strong partnership economics expected in 2026.

Three differentiated oncology assets advance toward pivotal milestones and commercial potential.

Advancing three late-stage oncology assets with major catalysts and strong commercial potential.

IPH4502, lacutamab, and Monalizumab advance in pivotal trials, with major data readouts expected in 2024.

Strong clinical progress, focused pipeline, and solid cash position support late-stage execution.

Late-stage oncology pipeline and strong partnerships drive near-term catalysts and growth.

Lead clinical programs advance toward key regulatory and commercial milestones in 2025–2026.

Lacutamab, IPH4502, and Monalizumab drive growth, with FDA milestones and strong cash position.

Lacutamab targets accelerated approval in Sézary syndrome by 2027, unlocking a larger CTCL market.

Refocused on three lead oncology assets, with robust cash runway and key clinical milestones ahead.

Advancing innovative antibody therapies in oncology with strong partnerships and late-stage assets.

Multiple late-stage assets and key data readouts position the pipeline for major milestones in 2025.

Advancing innovative oncology assets with strong cash runway and new Sanofi investment.